Sun, 3 March 2013
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
Direct download: GRACEcastUC-038_Lung-Video_Oxnard_on_AR_to_Targeted_Therapy.m4v
Category:Lung-Cancer-Video -- posted at: 6:12pm PDT